CRISPR Expands From One Approval Into a Full Clinical Pipeline in 2026

CRISPR Expands From One Approval Into a Full Clinical Pipeline in 2026

CRISPR gene editing enters mainstream medicine as Casgevy approval fuels a clinical trial pipeline for cancer, rare diseases, and autoimmune conditions with FDA cutting red tape.

LS
Linsey Smith
Jul 8, 2026
1 min read

According to the latest gene-editing clinical trials report, CRISPER is on the go to join mainstream medicine. Casgevy, the first CRISPR-based therapy to receive FDA approval, remains the standard-bearer for gene editing in medicine. Approved in December 2023 for sickle cell disease and subsequently for beta-thalassemia, it demonstrated that CRISPR could move from the lab to the clinic. In 2026, that single approval has grown into a sprawling pipeline of clinical trials spanning cancer, autoimmune diseases, and rare genetic conditions.

The FDA has also introduced a new regulatory pathway designed to cut red tape for bespoke gene therapies targeting rare diseases, a move that could accelerate the timeline for CRISPR-based treatments still in development. Meanwhile, CRISPR Therapeutics and competing firms are advancing multiple candidates through mid- and late-stage trials, with a focus on inherited blood disorders and oncology applications.

The question is no longer whether gene editing works. It does, at least for the conditions tested so far. The question is whether the clinical infrastructure, manufacturing capacity, and pricing models can scale to meet the demand that these therapies will generate.

About the Writer

More from Mindplex

Keep reading

Three more ideas worth your time.

Browse MindBytes

Discussion

Join the discussion

Sign in to share a response with the community.

Type @ to mention someone Type / or use + to add a block Highlight text, then choose Link
Loading editor

Comments cannot be edited after posting because they become part of the reputation record. Give yours a quick review first.